Peapod Lane Capital LLC Takes $994,000 Position in Assembly Biosciences, Inc. (NASDAQ:ASMB)

Peapod Lane Capital LLC acquired a new position in shares of Assembly Biosciences, Inc. (NASDAQ:ASMB - Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 62,970 shares of the biopharmaceutical company's stock, valued at approximately $994,000. Peapod Lane Capital LLC owned about 0.99% of Assembly Biosciences as of its most recent SEC filing.

Separately, JPMorgan Chase & Co. raised its holdings in shares of Assembly Biosciences by 5,137.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company's stock worth $53,000 after purchasing an additional 3,442 shares during the period. 19.92% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Assembly Biosciences

In other Assembly Biosciences news, Director Michael Houghton purchased 3,202 shares of the business's stock in a transaction that occurred on Monday, December 30th. The shares were acquired at an average price of $15.61 per share, for a total transaction of $49,983.22. Following the completion of the purchase, the director now owns 3,202 shares in the company, valued at $49,983.22. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 5.10% of the company's stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a "neutral" rating on shares of Assembly Biosciences in a report on Friday, December 27th.

Assembly Biosciences Stock Performance

Shares of NASDAQ:ASMB traded up $0.81 during midday trading on Monday, hitting $13.02. 48,610 shares of the company's stock traded hands, compared to its average volume of 21,819. The firm's fifty day moving average price is $14.90 and its two-hundred day moving average price is $15.64. Assembly Biosciences, Inc. has a twelve month low of $11.01 and a twelve month high of $19.93.

Assembly Biosciences Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.